Source comparison
Best BPC-157 Dosage Nerve Repair 2026: Protocol Comparison
The following table compares dosage protocols across nerve injury classifications, showing how dose, route, and frequency vary based on injury severity and treatment goals. | Injury Type | Daily Dosage | Administration Route | Injection Frequency | Treatment D
This comparison does not assign a generated winner or score.
- The following table compares dosage protocols across nerve injury classifications, showing how dose, route, and frequency vary based on injury severity and treatment goals.
- | Injury Type | Daily Dosage | Administration Route | Injection Frequency | Treatment Duration | Mechanism Targeted | Professional Assessment ||—|—|—|—|—|—|| Mild Compression (Carpal Tunnel, Cubital Tunnel) | 200–300 mcg | Subcutaneous (systemic) | Once daily | 4–8 weeks | Anti-inflammatory; Schwann cell support | Lowest effective dose for neuroprotection; sufficient for mild demyelination without structural axon damage || Moderate Crush Injury (Intact Epineurium) | 400–500 mcg | Subcutaneous or split dosing (SC + IM) | Twice daily (AM/PM) | 6–12 weeks | FAK-paxillin activation; axonal sprouting | Split dosing maintains stable plasma levels; consider IM component near injury site for localised effect || Severe Transection or Avulsion | 750–1,000 mcg | Intramuscular (local) + Subcutaneous (systemic) | Twice daily | 12–24 weeks minimum | VEGFR2 upregulation; neuromuscular junction preservation | Highest dose justified only when local administration near injury is feasible; systemic alone